Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants
May 5, 2021 at 10:55 am
Jesse Salk, CEO and co-founder of TwinStrand Biosciences. (TwinStrand Photo)
New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, technology, healthcare and life sciences. Total venture capital funding is now north of $70 million for the 6-year-old company.
Double strands of innovation: TwinStrand, which spun out of the University of Washington, has developed technology in both gene sequencing and analyzing sequencing results to help it find what the company calls “genetic needles in the haystack.”